OSAKA, Japan, February, 25, 2022 - Shionogi & Co., Ltd. (Headquarters: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") are pleased to announce the conclusion of a business cooperation agreement regarding support for children’s bright future (hereafter “the agreement”) with the City of Yokohama (Mayor: Takeharu Yamanaka).
Under the agreement, the City of Yokohama and Shionogi will collaborate to promote initiatives that help children to realize their future potential by conducting the activities below.
1. Efforts to support children with developmental disabilities and their families
2. Efforts to promote understanding of developmental disabilities
3. Efforts related to health support for children
4. Additional efforts in support of the overall goal
Shionogi believes that in Japan, where the birthrate is declining and the population is aging at an accelerating pace, it is necessary to create an environment in which children, who will lead the next generation, can spend their lives in good health and play an active role in realizing a sustainable society. As part of our efforts, we established the “Office for Children’s Bright Future” in FY2017 and have promoted initiatives that help children to realize their future potential in cooperation with various local governments. We will continue to contribute to the creation of a society in which each child can make the most of their individual abilities. We seek to support children’s growth, promote their health, and help them to overcome challenges in their lives.
In its new medium-term business plan “Shionogi Transformation Strategy 2030 (STS2030),” Shionogi has set “extension of healthy lifespan through total care” as one of the targets and has been working not only to provide medicines that improve patient’s symptoms but also to create an environment where patients receive medical care and services that address their needs in a timely manner, while also seeking to promote understanding and support from the people around them. We will strive to resolve social issues by strengthening partnerships with industry, government, and academia and continuing to provide new value to society, while refining the strengths we have cultivated as a drug discovery-type pharmaceutical company.
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html